gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.


Cholinesterase, butyrylcholinesterase, pseudocholinesterase
Mutant alleles at the BCHE locus are responsible for suxamethonium sensitivity. Homozygous persons sustain prolonged apnea after administration of the muscle relaxant suxamethonium in connection with surgical anesthesia. The activity of pseudocholinesterase in the serum is low and its substrate behavior is atypical. In the absence of the relaxant, the homozygote is at no known disadvantage. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: acetylcholinesterase, CAN, HAD, ACID, AGE
Papers on Cholinesterase
Therapeutic strategies for Alzheimer's disease in clinical trials.
Malawska et al., Kraków, Poland. In Pharmacol Rep, Feb 2016
Current treatment of the disease, essentially symptomatic, is based on three cholinesterase inhibitors and memantine, affecting the glutamatergic system.
Induced thiacloprid insensitivity in honeybees (Apis mellifera L.) is associated with up-regulation of detoxification genes.
Moores et al., Harpenden, United Kingdom. In Insect Mol Biol, Feb 2016
These included five P450s, CYP6BE1, CYP305D1, CYP6AS5, CYP315A1, CYP301A1, and a carboxyl/cholinesterase (CCE) CCE8.
Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.
Dash et al., Las Vegas, United States. In Cns Neurosci Ther, Feb 2016
Cholinesterase inhibitors may reduce the emergence of NPS and have a role in their treatment.
Repeated exposure to neurotoxic levels of chlorpyrifos alters hippocampal expression of neurotrophins and neuropeptides.
Stallings et al., Oak Ridge, United States. In Toxicology, Feb 2016
Neither dose of CPF caused overt clinical signs of cholinergic toxicity, although after 21days of exposure, cholinesterase activity was decreased to 58% or 13% of control levels in the hippocampus of rats in the 3 or 10mg/kg/d groups, respectively.
Species- and concentration-dependent differences of Acetyl- and Butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Zausig et al., Regensburg, Germany. In Neuropharmacology, Feb 2016
To evaluate the in vitro sensitivity of Acetyl- and Butyrylcholinesterase (AChE, BChE), we compared the concentration-response effects of physostigmine and neostigmine on cholinesterases in whole blood from rat and human.
Design and discovery of Novel Thiazole acetamide derivatives as anticholinesterase agent for possible role in the management of Alzheimer's.
Liu et al., Linyi, China. In Bioorg Med Chem Lett, Feb 2016
These compounds were evaluated for in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities for possible benefit in Alzheimers disease (AD).
Alkaloids pharmacological activities - Prospects for the development of phytopharmaceuticals for neurodegenerative diseases.
da Silva Araújob et al., Teresina, Brazil. In Curr Pharm Biotechnol, Jan 2016
A literature review was conducted in the databases PubMed, Science Direct, Scopus, Scielo and Google Academics using the following key words: alkaloids, pharmacology, neurodegenerative diseases, cholinesterase inhibitors, antidepressants, anti-inflammatories, antioxidant and anxiolytic.
Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials.
Rieckmann et al., Berlin, Germany. In Am J Geriatr Psychiatry, Dec 2015
Using comparable inclusion and exclusion criteria, we analyzed the efficacy of drug therapy (cholinesterase inhibitors, memantine, and Ginkgo biloba) and exercise interventions for improving cognition in AD and MCI populations.
Pharmacogenetics and anaesthetic drugs: Implications for perioperative practice.
Behrooz, Coventry, United Kingdom. In Ann Med Surg (lond), Dec 2015
Anaesthetics is an area of particular interest in this field, with previous research leading to better informed practice, specifically with regards to pseudocholinesterase deficiency and malignant hyperthermia.
Treatment for mild cognitive impairment: a systematic review and meta-analysis.
Raina et al., In Cmaj Open, Oct 2015
Cholinesterase inhibitor studies evaluating cognition (Alzheimer's Disease Assessment Scale, cognition subscale) showed no difference between intervention and control groups (mean difference [MD] -0.33, 95% CI -0.73 to 0.06]; one behavioural study showed no significant effect on cognition (Alzheimer's Disease Assessment Scale, cognition subscale) for the intervention group when compared to controls (MD -0.60, (95% CI -1.44 to 0.24), and one study on vitamin E showed no difference between intervention and control groups (MD 0.85, 95% CI -0.32 to 2.02).
Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.
Miller et al., San Francisco, United States. In Lancet Neurol, 2013
Enrolment numbers were lower than planned because of many patients' preference to take memantine or cholinesterase inhibitors off-label rather than participate in a clinical trial.
Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users.
Balagopal et al., Baltimore, United States. In Hepatology, 2012
BCHE may be involved in the pathogenesis of hepatitis C-related fibrosis among injection drug users.
Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis.
Morsch et al., Santa Maria, Brazil. In Biomed Pharmacother, 2012
AChE and BChE activities were decreased in prostate cancer patients
Evidence-based treatment of delirium in patients with cancer.
Alici et al., New York City, United States. In J Clin Oncol, 2012
Antipsychotics, cholinesterase inhibitors, and alpha-2 agonists are the three groups of medications that have been studied in randomized controlled trials in different patient populations.
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Phillips et al., London, United Kingdom. In N Engl J Med, 2012
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease.
Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease.
Geula et al., Halifax, Canada. In J Neuropathol Exp Neurol, 2012
Butyrylcholinesterase is associated with a subpopulation ofbeta-amyloid plaques and may play a role in Alzheimer's disease plaque maturation.
[Pseudocholinesterase activity in type 1 bipolar patients].
Najjar et al., Monastir, Tunisia. In Ann Biol Clin (paris), 2012
Compared with controls, bipolar patients had a significantly higher pseudocholinesterase activity.
Predictive value of serum cholinesterase for the prognosis of aged patients with systemic inflammatory response syndrome.
Chen et al., Hangzhou, China. In Chin Med J (engl), 2011
Serum ChE might be a predictive marker for the prognosis of aged patients with systemic inflammatory response syndrome, with low serum ChE levels indicating poor prognosis.
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
Slooter et al., Utrecht, Netherlands. In Lancet, 2010
We aimed to establish the effect of the cholinesterase inhibitor rivastigmine on the duration of delirium in critically ill patients.
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Tarenflurbil Phase 3 Study Group et al., Boston, United States. In Jama, 2010
Concomitant treatment with cholinesterase inhibitors or memantine was permitted.
share on facebooktweetadd +1mail to friends